glp-1 advertising crackdown news FEDS CRACK DOWN ON TELEHEALTH COMPANIES SELLING GLP-1s: The U.S. Food and Drug Administration is cracking down on telehealth companies for making “false and misleading” claims about compounded GLP-1 Advertising Boom - News

BPC-157 BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide discovered by Sikiric et al

Brand and Trademark Note: Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S

FIGURE 1 Inflammation Neuroinflammation is a key pathophysiological mechanism of secondary injury, as it can produce neurotoxic effects on neurons through oxidative stress, apoptosis, and excitotoxicity (Kumar and Loane, 2012), inducing a progressive cycle of chronic inflammation (Sulhan et al., 2020)

BPC-157, or Body Protection Compound-157, is a peptide therapy made up of 15 amino acids derived from a naturally occurring protein in the stomach

The mechanism of action of N-acetylcysteine (NAC): The emerging role of H(2)S and sulfane sulfur species

Dailey K